Better Coronavirus Stock: AstraZeneca or Johnson & Johnson
The world needs a COVID-19 vaccine, and the number of projects underway to develop one is astounding. Currently, 45 coronavirus vaccine candidates are in human trials, and 11 of those are have reached phase 3, when the vital questions of whether they work in the real world — and if so, how well — will be answered. Russia and China have already approved six vaccines for limited use, but none of those has completed testing in a large-scale phase 3 clinical trial.
The clearest way to evaluate companies producing vaccine candidates — and the financial gains that will likely follow — is to compare how those candidates. How are they designed to work? Do they work? When will they be available? And how important is a successful vaccine to a given company’s financial outlook?
Image source: Getty Images